BioXcel Therapeutics, Inc. (BTAI) financial statements (2021 and earlier)

Company profile

Business Address 555 LONG WHARF DRIVE
NEW HAVEN, CT 06511
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2133243
Cash and cash equivalents2133243
Receivables  0
Other undisclosed current assets420
Total current assets:2173443
Noncurrent Assets
Operating lease, right-of-use asset21
Property, plant and equipment110
Other noncurrent assets000
Total noncurrent assets:320
TOTAL ASSETS:2203644
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1185
Accounts payable452
Accrued liabilities733
Other liabilities00 
Other undisclosed current liabilities00 
Total current liabilities:1285
Noncurrent Liabilities
Long-term debt and lease obligation11 
Operating lease, liability11
Other undisclosed noncurrent liabilities(1)  
Total noncurrent liabilities:11 
Total liabilities:1395
Stockholders' equity
Stockholders' equity attributable to parent2072739
Common stock000
Additional paid in capital3468463
Accumulated deficit(139)(57)(24)
Total stockholders' equity:2072739
TOTAL LIABILITIES AND EQUITY:2203644

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Gross profit:0  
Operating expenses(82)(34)(20)
Other undisclosed operating loss(0)  
Operating loss:(82)(34)(20)
Interest and debt expense(0)  
Loss before gain (loss) on sale of properties:(82)(34)(20)
Other undisclosed net income 11
Net loss:(82)(33)(19)
Other undisclosed net income attributable to parent0  
Net loss available to common stockholders, diluted:(82)(33)(19)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(82)(33)(19)
Comprehensive loss, net of tax, attributable to parent:(82)(33)(19)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: